SPECIALIZED PRESS July 31, 2019 Not intended for U.S. and UK MediaU.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancerRead more
SPECIALIZED PRESS July 26, 2019 Not intended for U.S. and UK MediaBayer receives positive CHMP opinion for precision oncology treatment larotrectinib with first ever tumor-agnostic indication in in EuropeRead more
July 24, 2019 Bayer and White Ribbon Alliance announce three-year renewal of partnership to improve the every day health of women, infants and children through self-careRead more
SPECIALIZED PRESS July 18, 2019 Not intended for U.S. and UK MediaBayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga™ (regorafenib) and Opdivo™ (nivolumab) as combination therapy in patients with colorectal cancerRead more
SPECIALIZED PRESS July 15, 2019 Not intended for U.S. and UK Media - Magnetic Resonance Imaging (MRI):FDA approves Bayer's Gadavist™ as first and only contrast agent for use in cardiac MRI in patients with coronary artery diseaseRead more
July 11, 2019 Talent Awards from the Bayer Science & Education Foundation:New winners of Bayer Early Excellence in Science Award: EUR 30,000 for international research scientistsRead more
July 10, 2019 Bayer Trendlines Ag Innovation Fund to co-invest with Trendlines in new companyRead more
